Journal of Nanomedicine & Nanotechnology

Carriers for therapeutic delivery for coronary and cardiovascular disease and stroke

3^rd International Conference on Nanotek & Expo

December 02-04, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Shaoling Huang, Melvin E. Klegerman, Hyunggun Kim, Susan T. Laing, Patrick Kee, Yong-Jian Geng and David D. McPherson

Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

Ischemic stroke is the most common acute neurologic illness and, in 2008, accounted for more than $65 billion in costs. In the U.S., atherosclerosis continues to be the number one underlying cause of disability and death with annual estimated costsexceeding $431.8 billion. New methods of diagnosing and treating heart disease, stroke and their complications are needed. We have been developing ?intrinsically echogenic liposomes? (ELIP) as a platform technology for visualization and directed, controlled treatment of a wide variety of disorders. Intellectual property covers a broad technology using the ELIP platform with targeting for tissue highlighting and therapeutic delivery. Our proprietary production procedure causes very small air pockets to become entrapped inside the ELIP and in the ELIP membrane bilayer. Our ELIPs reflect ultrasound and are ?intrinsically? echogenic; 99% of ELIP are between 40 and 100 nm in size, making them truly a nanotechnology. With targeting, we have demonstrated ELIP highlighting of thrombi and various stages of atherosclerotic plaques in vitro and in vivo in preclinical studies, using five different molecular markers. Highlighting was demonstrated with conventional ultrasound techniques. We have developed the ELIP technology into a highly versatile therapeutic platform, featuring targeted, controlled release of agents with clinical Doppler ultrasound, with greater efficacy and less toxicity than conventional formulations of the same agents. Stealth transport of therapeutic agents and targeted delivery of these agents, triggered by application of ultrasound energy, is an advantage. These advantages fall into four major categories: 1. Drugs- We are exploring the clinical applicability of ELIP formulations of thiazolidinediones and bevacizumab for inhibiting atherosclerosis progression. A bevacizumab formulation also has obvious cancer applications.For liposomal-tPa formulation, see separate Fresh Air submission 2. Bioactive Gases- We have developed formulations that encapsulate bioactive gases and release them. These include ELIP- encapsulated nitric oxide (NO-ELIP) to increase therapeutic penetration into tissue beds; and noble gas encapsulation (Xenon) for tissue stabilization and protection ofneurons following acute stroke or myocardial cells following heart attack 3. Genes- For gene therapy of atherosclerosis 4. Stem Cells- See separate fresh air submission